Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH

Not Applicable

Recruiting

Conditions: Hemophagocytic Syndrome

Interventions: Drug: Cytoxan
Drug: Etoposide
Drug: Dexamethasone
Drug: Cyclosporine (CSA)

First Posted Date: 2023-07-07

Last Posted Date: 2023-08-30

Lead Sponsor: shifeng Lou

Target Recruit Count: 160

Registration Number: NCT05936086

Locations: 🇨🇳
The Second affiliated Hosptial of Chongqing medical University, Chongqing, China

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Small Cell Lung Cancer
SCLC
Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Monalizumab
Drug: Carboplatin or Cisplatin
Drug: Etoposide

First Posted Date: 2023-06-15

Last Posted Date: 2024-10-21

Lead Sponsor: Hirva Mamdani

Target Recruit Count: 38

Registration Number: NCT05903092

Locations: 🇺🇸
Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 1 locations

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Not Applicable

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Venetoclax
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Procedure: Hematopoietic Cell Transplantation
Drug: Melphalan

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-18

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 52

Registration Number: NCT05863845

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Phase 2

Recruiting

Conditions: SCLC

Interventions: Drug: PM8002
Drug: Platinum
Drug: Atezolizumab
Drug: Etoposide

First Posted Date: 2023-05-06

Last Posted Date: 2024-12-11

Lead Sponsor: Biotheus Inc.

Target Recruit Count: 445

Registration Number: NCT05844150

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 14 locations

Optimum Induction Therapy of Low-risk APL

Not Applicable

Recruiting

Conditions: Induction Therapy
Oral
Acute Promyelocytic Leukemia

Interventions: Drug: Etoposide
Drug: Daunorubicin

First Posted Date: 2023-04-27

Last Posted Date: 2024-05-10

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 74

Registration Number: NCT05832320

Locations: 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Ifosfamide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Biological: Tafasitamab

First Posted Date: 2023-04-20

Last Posted Date: 2024-11-15

Lead Sponsor: David Bond, MD

Target Recruit Count: 37

Registration Number: NCT05821088

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer Recurrent

Interventions: Drug: Debio 0123
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2023-04-18

Last Posted Date: 2024-12-20

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 78

Registration Number: NCT05815160

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 11 locations